Post

New research · Endocrinology
ESMO open · 1d
Case-controlESMO open · 2026

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

M Cruellas, A Rodriguez-Hernandez, L Carità … J Balmaña
Read paper
EndocrinologyCase-control

BRCA2 pathogenic variants are associated with shorter progression-free survival in metastatic breast cancer.

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

M Cruellas et al. · ESMO open · 2026
Background

The impact of homologous recombination repair (HRR) pathogenic variants (PV) on outcomes with first-line CDK4/6i plus ET in HR-positive/HER2-negative MBC remains uncertain.

Methods

We conducted a multicenter, real-world, case-control study including 233 patients with HR-positive/HER2-negative MBC treated with first-line CDK4/6i and ET.

n = 233 patients
Results

BRCA2 gene changes meant a higher risk of cancer getting worse or death

AHR 4.04 (95% CI 1.82 to 8.98)
null = 11.828.98
CI excludes the null - significant
More results

Among the included 233 patients, median age at diagnosis was 45 years (interquartile range 39-56) and 33% had de novo metastatic disease.

Primary resistance to adjuvant ET was present in 10% and secondary resistance in 27%.

More results

Among patients with endocrine-sensitive disease, germline BRCA2 PV carriers had markedly shorter PFS (median PFS 12 versus 39 months; aHR 4.04; 95% CI 1.82-8.98, P < 0.001).

Exploratory analyses revealed RB1 LOH before CDK4/6i-treatment in most evaluable BRCA2 tumors.

“
Conclusion · 1 of 2

BRCA2 PVs were independently associated with poorer outcomes to first-line CDK4/6i plus ET in HR-positive/HER2-negative MBC compared with controls, especially relevant among patients with endocrine-sensitive disease.

Conclusion · 2 of 2

These findings suggest that patients with a germline PV in BRCA2 may require alternative first-line strategies.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
P_adj = 0.038
early pregnancy ANGPTL4 levels were higher in women who developed gestational diabetes
Systematic Review
OR 1.58
patients with thyroid cancer have higher odds of accidental parathyroid gland removal
Review
21.5 per 100 000 persons
This is the number of US people with confirmed slow stomach emptying
Cohort Study
55.9% vs. 68.1%
Diabetic patients had lower major molecular response at 12 months (55.9% vs 68.1%).
Cohort Study
OR 18.90
far higher odds of fatty-liver inflammation with scarring at the top blood-marker level
Review
30-37%
SGLT2 inhibitors lower the chance of heart failure hospital stays and heart-related deaths
Cohort Study
0.5 %
only 0.5% of blood sugar tests after birth found lasting high blood sugar
Cohort Study
HR 1.095
a higher triglyceride to HDL cholesterol ratio means a higher risk of new diabetes